Literature DB >> 14532151

B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience.

T Shaw1, J Quan, M C Totoritis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14532151      PMCID： PMC1766758          DOI： 10.1136/ard.62.suppl_2.ii55

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  26 in total

1.  Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity.

Authors:  P E Lipsky
Journal:  Nat Immunol       Date:  2001-09       Impact factor: 25.606

Review 2.  Pathogenesis of rheumatoid arthritis. Role of B lymphocytes.

Authors:  Z Zhang; S L Bridges
Journal:  Rheum Dis Clin North Am       Date:  2001-05       Impact factor: 2.670

Review 3.  Role of B cells in the pathogenesis of rheumatoid arthritis: potential implications for treatment.

Authors:  A Gause; C Berek
Journal:  BioDrugs       Date:  2001       Impact factor: 5.807

Review 4.  B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders.

Authors:  J C W Edwards; M J Leandro; G Cambridge
Journal:  Biochem Soc Trans       Date:  2002-08       Impact factor: 5.407

5.  Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion.

Authors:  M J Leandro; J C W Edwards; G Cambridge
Journal:  Ann Rheum Dis       Date:  2002-10       Impact factor: 19.103

6.  Presence of a population of CD20+, CD38- B lymphocytes with defective proliferative responsiveness in the synovial compartment of patients with rheumatoid arthritis.

Authors:  C C Reparon-Schuijt; W J van Esch; C van Kooten; N P Ezendam; E W Levarht; F C Breedveld; C L Verweij
Journal:  Arthritis Rheum       Date:  2001-09

7.  T cell activation in rheumatoid synovium is B cell dependent.

Authors:  S Takemura; P A Klimiuk; A Braun; J J Goronzy; C M Weyand
Journal:  J Immunol       Date:  2001-10-15       Impact factor: 5.422

8.  An open study of B lymphocyte depletion in systemic lupus erythematosus.

Authors:  Maria J Leandro; Jonathan C Edwards; Geraldine Cambridge; Michael R Ehrenstein; David A Isenberg
Journal:  Arthritis Rheum       Date:  2002-10

9.  Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma.

Authors:  John D Hainsworth; Sharlene Litchy; Howard A Burris; Daniel C Scullin; Steven W Corso; Denise A Yardley; Lisa Morrissey; F Anthony Greco
Journal:  J Clin Oncol       Date:  2002-10-15       Impact factor: 44.544

10.  Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells.

Authors:  Salvatore De Vita; Francesco Zaja; Stefania Sacco; Alessandro De Candia; Renato Fanin; Gianfranco Ferraccioli
Journal:  Arthritis Rheum       Date:  2002-08
View more
  32 in total

Review 1.  [Biologicals: a new therapeutic approach for inflammatory diseases].

Authors:  C E Antoni; B Manger
Journal:  Internist (Berl)       Date:  2004-06       Impact factor: 0.743

Review 2.  Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease.

Authors:  Arnd Heiligenhaus; Stephan Thurau; Maren Hennig; Rafael S Grajewski; Gerhild Wildner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-08-25       Impact factor: 3.117

3.  Effects of rituximab in two patients with dysferlin-deficient muscular dystrophy.

Authors:  Alberto Lerario; Filippo Cogiamanian; Chiara Marchesi; Marzia Belicchi; Nereo Bresolin; Laura Porretti; Yvan Torrente
Journal:  BMC Musculoskelet Disord       Date:  2010-07-11       Impact factor: 2.362

4.  Expression and biological characterization of an anti-CD20 biosimilar candidate antibody: a case study.

Authors:  Denise Dorvignit; Julio L Palacios; Maylin Merino; Tays Hernández; Katya Sosa; Angel Casaco; Alejandro López-Requena; Cristina Mateo de Acosta
Journal:  MAbs       Date:  2012-07-01       Impact factor: 5.857

Review 5.  How do follicular dendritic cells interact intimately with B cells in the germinal centre?

Authors:  Chan-Sik Park; Yong Sung Choi
Journal:  Immunology       Date:  2005-01       Impact factor: 7.397

6.  Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis.

Authors:  E Janas; R Priest; J I Wilde; J H White; R Malhotra
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

7.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; P Emery; E C Keystone; M H Schiff; P L C M van Riel; M E Weinblatt; M H Weisman
Journal:  Ann Rheum Dis       Date:  2006-11       Impact factor: 19.103

Review 8.  B-cell inhibitors as therapy for rheumatoid arthritis: an update.

Authors:  Jennifer Kwan-Morley; Daniel Albert
Journal:  Curr Rheumatol Rep       Date:  2007-10       Impact factor: 4.592

Review 9.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

10.  Efficacy of B cell depletion in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor alpha agents: an open-label observational study.

Authors:  L Brulhart; A Ciurea; A Finckh; A Notter; J M Waldburger; D Kyburz; C Gabay
Journal:  Ann Rheum Dis       Date:  2006-03-15       Impact factor: 19.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.